These results from animal models of mouse mammary and human colon cancers demonstrate that systemic inhibition of the Ras/MEK pathway significantly improves the in vivo therapeutic efficacy of 5-ALA-PDT. This evidence concerns the gene MAP2K7 and colonic neoplasm.